Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period ...